What we would need to randomise to answer this properly
One randomised trial has combined a GLP-1 receptor agonist with supervised exercise. Its result is the single most useful piece of evidence in this area.
October 2024
Everything filed in October 2024, the month of Volume 1, Number 10. The issue itself — cover, editor’s letter and table of contents — is here.
Nigeria caps tirzepatide prescribing to 6 specialist centres
Efficacy was never the question in this appraisal. Duration of treatment was.
Calder Vale Peptides of Skipton enters a consent decree and stops sterile preparation
The observation that closes a facility is rarely the dramatic one.
A shortage listing ends. 5 pharmacies now have a business model and no legal basis for it.
The document is four pages. Three of them are about dates.
Discontinuation rates, read honestly
Roughly four to seven per cent of trial participants discontinued for adverse events, mostly gastrointestinal, mostly during escalation. That is the empirical size of the…
What Janoshik would need in order to certify sterility, and why it does not
The absence of microbiological capability in this market is a commercial fact with a straightforward explanation, and it is worth understanding before blaming anybody for it.
Brazil declines to reimburse dulaglutide outside a specialist service
Efficacy was never the question in this appraisal. Duration of treatment was.
The relabeller trading as Vantris Bio closes after 8 years
A proper account of an operation that existed, and of what closing it cost.
What the new Poland guidance says about stopping
The evidence base is thin and the document says so, which is to its credit.
FLOW extension data: what happens after the trial stops
A design note rather than a result: what the comparator was, and what that permits you to conclude.
The retest date and the expiry date are not the same document
We asked twenty companies three questions about stability data and print every answer, refusal and non-response.
Non-responders, and the honest state of the evidence about them
A catalogue of open questions, with an assessment of how likely each is to be resolved.
Why summer is a documented quality problem in this trade
The route did not close because of a rule about peptides.
The slide that was not in the abstract
Reported from the sessions, and from the two hours afterwards.
A supplier suspends shipping to India after 14 consecutive customs detentions
The route did not close because of a rule about peptides.
PIONEER 6 misses on a secondary endpoint the coverage has not mentioned
A design note rather than a result: what the comparator was, and what that permits you to conclude.
Side effects, cost, supply, target: four reasons with four trajectories
Cost is the modal reason for discontinuation in every dataset we have seen, and it is absent from the clinical literature.
Two sessions a week, and the evidence behind the prescription
The recommendation survives scrutiny. The reasoning offered for it frequently does not.
SELECT misses on a secondary endpoint the coverage has not mentioned
A design note rather than a result: what the comparator was, and what that permits you to conclude.
The Netherlands declines to reimburse exenatide outside a specialist service
Efficacy was never the question in this appraisal. Duration of treatment was.
The online reseller trading as Adamant Research Supply closes after 13 years
A proper account of an operation that existed, and of what closing it cost.
The dose that got you here and the dose that keeps you here
The commonest real-world strategy in this drug class is the least studied one.
Repackaging, subdivision, and the batch number that changed hands
A document is only as good as the chain that connects it to the material, and most chains here are two or three links longer than the paperwork admits.
What the trials counted as intolerance
We set out the questions that distinguish a symptom to manage from a dose to change.
SELECT extension data: what happens after the trial stops
A design note rather than a result: what the comparator was, and what that permits you to conclude.
Holograms, QR codes and other things that are not verification
Reported from the analysis, not from a warning notice.
The relabeller trading as Vantris Bio enters a consent decree and stops sterile preparation
The observation that closes a facility is rarely the dramatic one.
A supplier suspends shipping to Italy after 10 consecutive customs detentions
The route did not close because of a rule about peptides.
What SURPASS-4 tells us about maintenance, and what it does not
A survey of the maintenance evidence, which is shorter than the survey of the withdrawal evidence.
Independent analysis puts a QST dulaglutide lot at 95.3%, against 91.7% on the certificate
The result is unremarkable. What the report omits is not.
Tianjin export categories for peptide intermediates were quietly renamed
Follow the resin, not the catalogue.
From the floor in Suzhou: 15 posters, one theme
Reported from the sessions, and from the two hours afterwards.
Why summer is a documented quality problem in this trade
The route did not close because of a rule about peptides.
Why your endoscopist wants to know about your injection
Holding a dose before a procedure has a kinetic problem: a weekly drug with a seven-day half-life cannot be cleared by skipping one injection.
The degradation product that elutes underneath the parent peak
An isoaspartate rearrangement changes the molecule and not the mass. A method that confirms identity by molecular weight alone will report it as the parent compound.
What a 37% rise in coupling-reagent prices does to a 2 mg vial
Follow the resin, not the catalogue.
The 6-day notice: how a compounding wind-down works in New Zealand
The document is four pages. Three of them are about dates.
The relabeller trading as Vantris Bio closes after 12 years
A proper account of an operation that existed, and of what closing it cost.
A needle is a single-use instrument
For licensed products the in-use period is established by stability data. For a peptide reconstituted at home there is no such data, and the honest answer is that nobody…
GIP was a failed target for thirty years. Then it was not.
The glucagon arm raises energy expenditure and also raises hepatic glucose output. Balancing those is the whole engineering problem.